Encainide-induced diabetes: analysis of islet cell function.
OBJECTIVE
The purpose of this study was to gain insight into the mechanisms responsible for encainide-induced diabetes. Specifically, we sought to determine if absolute insulinopenia was present or whether encainide-induced diabetes was metabolically more like type II than type I diabetes.


METHODS
Islet function was assessed in a 65 year old white male with encainide-induced diabetes. After 6 months of encainide treatment and 2 months duration of diabetes, C-peptide, glucagon, and glucose levels were measured at baseline and at 30 minute intervals for 120 minutes following an oral mixed meal. These measurements allowed assessment of islet beta and alpha cell function in comparison to control data from our laboratory.


RESULTS
In this patient with encainide-induced diabetes, basal and peak C-peptide concentrations were similar to controls although peak C-peptide occurred substantially later than in controls. At peak glucose, the patient's C-peptide/glucose ratio was low indicating relative (but not absolute) insulinopenia. At baseline, glucagon was relatively depressed. Following Sustacal, there was an increase in glucagon of 100% over baseline compared to a mean glucagon rise in controls of only 8%. There was no serological evidence for autoimmune diabetes as islet cell autoantibodies were absent.


CONCLUSIONS
Similar to other forms of diabetes, encainide-induced diabetes is a bihormonal disorder. The metabolic pattern was more like type II than type I diabetes with C-peptide secretion in the normal range, yet persistent hyperglycemia that suggests relative insulinopenia and concurrent insulin resistance.
Winter
W E
WE
University of Florida, Department of Pathology and Laboratory Medicine, Gainesville.
Funahashi
M
M
Koons
J
J
D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000139:chemically induced*; D004032:Diet; D016700:Encainide / Q000009:adverse effects*; D005934:Glucagon / Q000097:blood; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000473:pathology; D007333:Insulin Resistance; D007515:Islets of Langerhans / Q000187:drug effects* / Q000473:pathology; D008297:Male
D001786:Blood Glucose; D002096:C-Peptide; D005934:Glucagon; D016700:Encainide